Walgreens Boots Alliance, Inc. (WBA)
| Previous Close | 17.26 |
| Open | 17.28 |
| Bid | 17.26 x 800 |
| Ask | 17.36 x 800 |
| Day's Range | 17.25 - 17.57 |
| 52 Week Range | 17.24 - 32.89 |
| Volume | |
| Avg. Volume | 11,652,519 |
| Market Cap | 14.925B |
| Beta (5Y Monthly) | 0.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.00 (5.79%) |
| Ex-Dividend Date | May 20, 2024 |
| 1y Target Est | N/A |
- ACCESSWIRE
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
Joint collaborations bring Boehringer Ingelheim's Phase III clinical trial to communities through Walgreens pharmacy clinical trial centers and EmVenio's mobile research units, aimed at improving access to trials Originally published by Walgreens ...
- Business Wire
Walgreens Boots Alliance Declares Quarterly Dividend
DEERFIELD, Ill., April 25, 2024--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, unchanged from the previous quarter. The dividend is payable on June 12, 2024, to stockholders of record as of May 21, 2024.
- Business Wire
Walgreens Launches Gene and Cell Services as Part of Newly Integrated Walgreens Specialty Pharmacy Business
DEERFIELD, Ill., April 25, 2024--Walgreens is expanding its specialty pharmacy services and investing in its capabilities as the company further grows its core pharmacy business to improve patient outcomes and provide greater value to payers and partners. The company today introduced Walgreens Specialty Pharmacy, a holistic offering that expands access to care for patients with complex, chronic conditions and enables partnerships that drive profitability for Walgreens’ pharmacy business. The com
